Contrasting roles for CXCR2 during experimental colitis
Introduction
There is ample evidence from the clinical and experimental setting supporting a crucial role for neutrophils in tissue ulceration and inflammation during inflammatory bowel disease (IBD) including Crohn's disease and ulcerative colitis Anezaki et al., 1998, Daig et al., 1996, Izzo et al., 1992, Keshavarzian et al., 1999. As a result, in recent years, much effort has been focused on characterizing further the role played by endogenous mediators in promoting neutrophil recruitment during active IBD. There is now a growing realization that chemokines may facilitate neutrophil recruitment during acute colitis Anezaki et al., 1998, Daig et al., 1996, Izzo et al., 1992, Keshavarzian et al., 1999.
Chemokines constitute a family of small (∼8–15 kDa) structurally related proteins that are widely regarded as one of the most important regulators of leukocyte trafficking and activation during the inflammatory process (Luster, 1998). The notion that chemokines could contribute to the pathogenesis of IBD stems from a series of clinical studies published a decade ago, in which rectal biopsies of patients with active ulcerative colitis or Crohn's disease were observed to produce high levels of the human chemokine CXCL8/IL-8 Anezaki et al., 1998, Izzo et al., 1992, Keshavarzian et al., 1999. Subsequent studies by Mazzucchelli et al. (1994) and Daig et al. (1996) showed that the expression of CXCL8/IL-8 correlated with the severity of inflammation and notably, this chemokine accounted for the majority of the leukocyte chemotactic activity that could be extracted from the inflamed colon Anezaki et al., 1998, Izzo et al., 1992, Keshavarzian et al., 1999.
The CXC chemokine CXCL1/KC (the murine analogue of CXCL8/IL-8; Boisvert et al., 1998, Luster, 1998, Terkeltaub et al., 1998) is a potent neutrophil chemoattractant in vivo Belperio et al., 2002, Bhatia et al., 2000, Boisvert et al., 1998, Podolin et al., 2002, Schuh et al., 2002a, and increases in the expression of this chemokine are associated with the progression of inflammatory diseases including hepatic injury (Campbell et al., 2003) and pancreatitis (Bhatia et al., 2000). CXCR2 is the sole receptor through which CXCL1/KC mediates its biological effects Belperio et al., 2002, Boisvert et al., 1998, Podolin et al., 2002, Schuh et al., 2002a, and a major mediator of neutrophil influx during an inflammatory response as reported in disease models of arthritis (Podolin et al., 2002) as well as allergic (Schuh et al., 2002a) and respiratory diseases (Belperio et al., 2002).
The present study assessed the biological role of CXCR2 during trinitrobenzene sulfonic (TNBS) acid-induced colitis.
Section snippets
Animals
Male Wistar rats (175 ± 20 g) were purchased from Charles River Breeding Farms Limited (Montreal, Canada). The animals were fed a standard chow pellet diet, had free access to water and were maintained on a 12-h light/dark cycle. All procedures were approved by the Animal Care Committee of the University of Calgary and were performed in compliance with the guidelines of the Canadian Council on Animal Care.
Induction of colitis
Rats were lightly anesthetized with Halothane and the hapten TNBS (60 mg/ml in 0.5 ml of
Neutrophil accumulation during TNBS-induced colitis
As previously documented Ajuebor et al., 2000, Ajuebor et al., 2001, Galvez et al., 2000, intracolonic administration of TNBS caused a time-dependent increase in neutrophil accumulation in the colon with significant increases within 8 h of colitis induction and remained elevated to day 7 of colitis induction (see MPO activity; Fig. 1).
CXCL1/KC and CXCR2 expression during TNBS-induced colitis
The finding of increased neutrophil accumulation in the colon led us to hypothesize that neutrophil chemoattractants such as the CXC chemokine CXCL1/KC, and its
Discussion
Over the past decade, a wealth of evidence has been generated to support a crucial role for neutrophils in the pathogenesis of colitis. Evidence that colonic neutrophil infiltrates contribute to the progression of colitis stems from a series of clinical studies in which increased neutrophil accumulation is observed in rectal biopsies of patients with active IBD relative to healthy controls Ajuebor and Swain, 2002, Anezaki et al., 1998, Daig et al., 1996, Izzo et al., 1992, Keshavarzian et al.,
Acknowledgements
This work was supported by a grant from the Canadian Institute of Health and Research (CIHR). Maureen N. Ajuebor is supported by a Canadian Association of Gastroenterology/Schering/CIHR post-doctoral fellowship.
References (23)
- et al.
Increased interleukin-8 (IL-8) in rectal dialysate from patients with ulcerative colitis: evidence for a biological role for IL-8 in inflammation of the colon
Am. J. Gastroenterol.
(1999) - et al.
Role of chemokines and chemokine receptors in the gastrointestinal tract
Immunology
(2002) - et al.
Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis
Am. J. Physiol., Gastrointest. Liver Physiol.
(2000) - et al.
The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat
J. Immunol.
(2001) - et al.
Correlations between interleukin-8, and myeloperoxidase or luminol-dependent chemiluminescence in inflamed mucosa of ulcerative colitis
Intern. Med.
(1998) - et al.
Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury
J. Clin. Invest.
(2002) - et al.
Treatment with neutralising antibody against cytokine induced neutrophil chemoattractant (CINC) protects rats against acute pancreatitis associated lung injury
Gut
(2000) - et al.
A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice
J. Clin. Invest.
(1998) - et al.
Neutrophil-independence of the initiation of colonic injury. Comparison of results from three models of experimental colitis in the rat
Dig. Dis. Sci.
(1994) - et al.
CINC-1 is an acute-phase protein induced by focal brain injury causing leukocyte mobilization and liver injury
FASEB J.
(2003)
Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease
Gut
Cited by (30)
CXCL8 chemokine in ulcerative colitis
2021, Biomedicine and PharmacotherapyCitation Excerpt :In accordance with this study, antagonist SB225002 attenuated the severity of colitis in a DSS-induced paired immunoglobulin-like type 2 receptor alpha (PILRα)-deficient mice model [104]. CXCR2 neutralizing antibodies can inhibit the recruitment of neutrophils in the colon during the early phase (i.e. 8 h) of TNBS-induced rat colitis model [105]. Several studies verified that mice with CXCR2 gene deletion were protected against DSS-induced colitis, which is characterized by alleviation of weight loss and histologic damage, reduced neutrophil infiltration into the mucosa and expression levels of the pro-inflammatory cytokines [106,107].
Immunomodulatory effects of Bifidobacterium bifidum 231 on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats
2017, Research in Veterinary ScienceCitation Excerpt :Treatment with BIF 231 or dexamethasone achieved inflammatory remission in the form of reduced macroscopic and histopathological changes. Adherence of BIF 231 to the intestinal epithelium and inhibition of macrophages and neutrophils infiltration can account for the intestinal anti-inflammatory effect, given the important role attributed to these cells in the inflammatory process (Ajuebor et al., 2004). In conclusion, our results showed positive correlation between in vitro adhesion and immunomodulatory properties with in vivo studies where BIF 231 facilitated the recovery of the damaged tissue in TNBS- induced colitis by adherence to the intestinal epithelium and modulation of imbalance between pro- and anti-inflammatory cytokines.
Neutrophils in animal models of autoimmune disease
2016, Seminars in ImmunologyCitation Excerpt :In the trinitrobenzene sulfonic acid (TNBS) colitis model (which tends to produce a more chronic inflammatory process than DSS), treatment with a blocking anti-CXCL1 antibody or a pharmacologic CXCR2 antagonist also significantly reduces inflammation, neutrophil influx, intestinal myeloperoxidase activity, IL-1β, CXCL1 and CXCL2 levels [119]. It is intriguing that while the early phases of the TNBS-induced acute colitis depend on the CXCR2 receptor, later phases seem to be CXCR2-independent, suggesting, as in other inflammatory diseases, that neutrophils affect early phases of the inflammatory response potentially by altering vascular permeability [120]. Blocking integrin β2 (CD18) also results in a significant decrease of myeloperoxidase activity and the concomitant mucosal permeability in the TNBS-induced acute colitis model, pointing again at a pathological role for neutrophils in experimental colitis [121,122].
A chemokine receptor CXCR2 macromolecular complex regulates neutrophil functions in inflammatory diseases
2012, Journal of Biological ChemistryCitation Excerpt :Activation of CXCR2 by its cognate ligands induces intracellular signals associated with chemotaxic migration, and recruitment and infiltration of leukocytes (especially PMNs) from the bloodstream during inflammation (52). It has been well documented that blocking the ELR+ CXC chemokines/CXCR2 biological axis via CXCR2 neutralizing antibodies or selective CXCR2 antagonists (such as SB225002) or neutralizing antibodies against cognate CXCR2 ligands (such as anti-CXCL1/keratinocyte-derived chemokine antibody) potently inhibited neutrophil migration and infiltration in vitro and in vivo, and significantly ameliorated ulcerative colitis in experimental animals (7, 35, 53–57). Genetic deletion of CXCR2 in colitic mice demonstrated reduced PMN infiltration, limited signs of mucosal damage, and reduced clinical symptoms (35, 58).
The collagen-breakdown product N-acetyl-Proline-Glycine-Proline (N-α-PGP) does not interact directly with human CXCR1 and CXCR2
2010, European Journal of PharmacologyThe role of CCL3/macrophage inflammatory protein-1α in experimental colitis
2004, European Journal of Pharmacology